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DObjective: Functional ischemic mitral regurgitation is a complication of ventricular remodeling; standard ther-
apy is reduction annuloplasty and coronary artery bypass grafting. Unfortunately, outcomes are retrospective
and contradictory. We report a multicenter study that documents the outcomes of reduction annuloplasty for
functional ischemic mitral regurgitation.
Methods: Twenty-one centers randomized 75 patients to the coronary artery bypass grafting þ reduction an-
nuloplasty subgroup that was the control arm of the Randomized Evaluation of a Surgical Treatment for Off-
pump Repair of the Mitral Valve trial. Entry criteria included patients requiring revascularization, patients
with severe or symptomatic moderate functional ischemic mitral regurgitation, an ejection fraction 25% or
greater, a left ventricular end-diastolic dimension 7.0 cm or less, and more than 30 days since acute myocardial
infarction. All echocardiograms were independently scored by a core laboratory. Reduction annuloplasty was
achieved by device annuloplasty. Two patients underwent immediate intraoperative conversion to a valve re-
placement because reduction annuloplasty was unable to correct mitral regurgitation; as-treated results are pre-
sented.
Results: Thirty-day mortality was 4.1% (3/73). Patients received an average of 2.8 bypass grafts. Mean follow-
up was 24.6 months. Mitral regurgitation was reduced from 2.6 0.8 preoperatively to 0.3 0.6 at 2 years. Free-
dom from death or valve reoperation was 78% 5% at 2 years. There was significant improvement in ejection
fraction and New York Heart Association class with reduction of left ventricular end-diastolic dimension. Cox
regression analyses suggested that increasing age (P¼ .001; hazard ratio, 1.16 per year; 95% confidence interval,
1.06–1.26) and renal disease (P¼ .018; hazard ratio, 3.48; 95% confidence interval, 1.25–9.72) were associated
with decreased survival.
Conclusions: Coronary artery bypass grafting þ reduction annuloplasty for functional ischemic mitral regur-
gitation predictably reduces mitral regurgitation and relieves symptoms. This treatment of moderate to severe
mitral regurgitation is associated with improved indices of ventricular function, improved New York Heart
Association class, and excellent freedom from recurrent mitral insufficiency. Although long-term prognosis re-
mains guarded, this multicenter study delineates the intermediate-term benefits of such an approach. (J Thorac
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Functional ischemic mitral regurgitation (FIMR) is a fre-
quent end-stage complication of coronary artery disease
caused by ventricular remodeling. With increasing ventric-
ular size, the mitral annulus dilates and papillary muscle
displacement tethers leaflets, causing functional mitral re-
gurgitation (FMR). This further impairs ventricular func-
tion with the progression of negative left ventricular (LV)ardiovascular Surgery c Volume 141, Number 1 91
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
FDA ¼ Food and Drug Administration
FIMR ¼ functional ischemic mitral regurgitation
FMR ¼ functional mitral regurgitation
HR ¼ hazard ratio
LV ¼ left ventricular
LVED ¼ left ventricular end diastolic
MR ¼ mitral regurgitation
RA ¼ reduction annuloplasty
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D remodeling.1,2 Current treatments for LV dysfunction with
FMR include medical therapy and surgery. With viable
ischemic myocardium, revascularization prevents further
damage, relieves the contributing ischemia, and may
stop or reverse the remodeling process. The effect of
correcting the ischemia alone on valve function has been
unpredictable and often transient, leaving the majority of
patients with residual, recurrent, or progressive mitral
regurgitation (MR).3 Significant MR is treated by valve re-
pair or replacement. Mitral repair is primarily done with
a reduction annuloplasty (RA), whereby an undersized an-
nuloplasty device increases the coaptive leaflet margin
and eliminates regurgitation.4 Current surgical techniques
for FMR have significant procedural risk, and the late out-
comes remain guarded.5 Although valve repair is generally
believed to be superior to replacement, replacement is
sometimes recommended in patients with significant leaflet
tethering who are considered high risk for recurrence.6
Thus, the gold standard therapy for FIMR is RA and cor-
onary artery bypass grafting (CABG) when appropriate.
Outcome data are retrospective, limited to individual series,
and somewhat contradictory. This report details a prospec-
tive, multicenter, independently monitored and audited
study that documents the outcomes of RA for FIMR using
core laboratory reviewed data.MATERIALS AND METHODS
Twenty-one centers (Appendix 1) randomized 75 patients to
a CABGþRA as a stratum in the control arm of the Randomized Evalua-
tion of a Surgical Treatment for Off-pump Repair of the Mitral Valve trial.
This Food and Drug Administration (FDA)-approved investigational de-
vice trial (Clinical Trials ID¼ NCT00120276) compared CABG plus ven-
tricular reshaping (Coapsys; Myocor Inc, Maple Grove, Minn) with
CABGþRA; the primary, comparative outcomes have been reported.7 Pa-
tients were on average 65.8 years old and predominately male (86.3%).
Table 1 contains patient demographic information for the 75 randomized
patients. The FDA’s study entry criteria favored the exclusion of particu-
larly high-risk surgical candidates to evaluate differences in midterm sur-
vival. Entry criteria included patients requiring revascularization,
patients with severe FIMR (or symptomatic moderate FIMR), an ejection
fraction 25% or greater, an LV end-diastolic (LVED) dimension 7.0 cm92 The Journal of Thoracic and Cardiovascular Surgeor less, and more than 30 days since an acute transmural myocardial infarc-
tion. Appendix 2 shows full inclusion/exclusion criteria. All echocardio-
grams were independently reviewed and scored by a core laboratory
(Mayo Clinic). MR severity was graded as 0 ¼ none, 1 ¼ mild,
2 ¼ moderate, 3 ¼ moderate–severe, and 4 ¼ severe. RA was achieved
by band or ring annuloplasty; the type of annuloplasty device was chosen
at the surgeon’s discretion. Two patients underwent intraoperative conver-
sion to chordal sparing mitral valve replacement due to an inability to cor-
rect MR with RA. The as-treated results are presented.
This study was approved by each participating medical center’s institu-
tional review board. Adverse events were adjudicated by an independent
Clinical Events Committee, and results were monitored by a Data Safety
Monitoring Board. The trial was initiated as a feasibility study in April
2003 and expanded with FDA approval into a pivotal study in June 2004.
This study was prematurely terminated when the sponsor failed to secure
ongoing funding in October 2008. At the time of closure, 165 patients
had been randomized. Mean follow-up was 24.6 months. The database
was maintained in Clindex (FORTRESS Medical Systems, Hopkins,
MN), and statistical analyses, such as mixed model and multivariable Cox
regression, were performed using SAS (SAS Institute Inc, Cary, NC) and
SPSS (SPSS Inc, Chicago, IL). Mean and standard deviations are reported.RESULTS
Operative mortality was 4.1% (3/73). Patients received
a mean of 2.8 bypass grafts. Multivariable Cox regression
analyses revealed that older age (P ¼ .001; hazard ratio
[HR] ¼ 1.16/y; 95% confidence interval [CI], 1.06–1.26)
and the presence of renal disease (P ¼ .018; HR ¼ 3.48;
95%CI, 1.25–9.72) were associatedwith decreased survival.
Renal disease (P¼ .007; HR¼ 3.8; 95%CI, 1.5–10.0), older
age (P ¼ .055; HR ¼ 1.1, 95% CI, 0.99–1.1), and LV end-
systolic volume index (P ¼ .091, HR ¼ 1.02, 95% CI,
0.99–1.04) were associated with decreased freedom from
death, reoperation, or recurrent MR (moderate or worse).
MR severity was significantly reduced from 2.54  0.80
at baseline to 0.52  0.66 and 0.35  0.63 at 1 and 2 years,
respectively (Table 2). Two patients had RA performed
without impact on MR grade and had to be intraoperatively
converted to mitral replacement; these patients were ex-
cluded from this as-treated analysis. In total, 12 patients
(16.1%) had moderate or worse recurrent MR during
follow-up. The technical details of these patients are in-
cluded in Appendix 3.
Five patients had moderate MR at discharge and a 48%
2-year survival; however, this was not statistically signifi-
cant when compared with all patients (P¼ .45). One patient
had recurrent MR (mild at discharge and moderate–severe
at 1 year) with reoperative valve replacement at 15 months.
This patient’s baseline LVED dimension was 6.3 cm with
a baseline ejection fraction of 40%.
Table 3 summarizes the functional and dimensional
changes. Ejection fraction significantly improved from
38% to 47% at 2 years. Reverse remodeling was evident
with significant decreases in end-diastolic and end-
systolic dimensions. New York Heart Association class sig-
nificantly improved in the majority of patients; 65.9% im-
proved 1 or more grades at 1 year and 72.0% at 2 years.ry c January 2011
TABLE 1. Demographics and disease characteristics in the 75 patients
randomized to bypass and reduction annuloplasty
Mean/no. Range N missing
Age (y) 65.6  8.7
LVEF (%) 38.3  10.3
Weight (kg) 82.2  19.8
MR (0–4)* 2.86  0.7
No. grafts 2.76  1.0 1–6
Male gender 63 (84%) 1.4%
NYHA class
I 5 (6.7%) 4.0%
II 31 (41.3%)
III 36 (48.0%)
IV 0 (0%)
No. of grafts performed
1 8 (10.7%) 1.3%
2 18 (24.0%)
3 35 (46.7%)
4 11 (14.7%)
5 1 (1.3%)
6 1 (1.3%)
Diabetes 42 (56%) 2.7%
Renal insufficiency 20 (26.7%) 1.3%
Smoking
Current 20 (26.7%) 1.3%
Previous 34 (45.3%)
Non 20 (26.7%)
PVD 16 (21.3%) 5.3%
History of CHF 48 (64.0%) 2.7%
History of MI
Anterior 10 (13.3%) 1.3%
Inferior 24 (32.0%)
Lateral 5 (6.7%)
History of stroke 6 (8.0%) 5.3%
Prior CABG 0 (0%) 2.7%
History of PCI 11 (14.7%) 2.7%
History of atrial fibrillation 20 (26.7%) 10.7%
History of ICD 1 (1.3%) 1.3%
LVEF, Left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York
Heart Association; PVD, peripheral vascular disease; CHF, congestive heart failure;
MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutane-
ous coronary intervention; ICD, implantable cardioverter defibrillator. Continuous
variables are presented as mean  standard deviation. *MR grades: 0 ¼ none,
1 ¼ mild, 2 ¼ moderate, 3 ¼ moderate-severe, 4 ¼ severe.
TABLE 2. Echocardiography core laboratory distribution of mitral
insufficiency grades in 70 patients* treated by coronary artery
bypass grafting and mitral repair
Baseline N Predischarge 1 y 1.5 y 2 y
None 0 41 25 19 19
Mild 5 11 19 12 5
Moderate 31 5 1 2 2
Moderate-severe 25 0 1 0 0
Severe 9 0 0 0 0
*Missing 3 baseline evaluations.
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shown in Table 4.
Avariety of annuloplasty devices from differentmanufac-
turers were used, ranging in size from 24 mm to 30 mm
(mean, 27 mm). Some 20.6% of the devices were soft and
not rigid or semi-rigid. Neither annuloplasty device type
(rigid/soft or complete/band) nor size affected recurrent
MR alone or the combined end point of freedom from death,
valve reoperation, or recurrent MR. Late systolic mitral
valve tenting area and diastolic annular area were analyzed
along with the aforementioned factors; only mitral valve
tenting area was weakly associated with any reoccurrence
of MR (P ¼ .18).The Journal of Thoracic and CDISCUSSION
This study provides benchmark outcomes data for the
surgical strategy of CABGþ RA for coronary artery dis-
ease and FMR. The short-term mortality of 4.1% is better
than that reported by the Society of Thoracic Surgeons and
others, but we have enlisted a ‘‘non–high-risk’’ patient co-
hort as dictated by the trial design with ejection fraction,
age, LVED dimension, and non-emergency surgery restric-
tions. The midterm results, however, are nearly identical to
what has been reported. Recent publications on CABG and
mitral repair for FMR indicate that mortality rates are sim-
ilar to those of the CABGþmitral valve repair stratum of the
Randomized Evaluation of a Surgical Treatment for Off-
pump Repair of the Mitral Valve, with a weighted 1-year
mortality rate of 19%.1,5,8-13 It is important to note that
these data represent the first prospective, multicenter
evaluation of surgical treatment of FMR. Significant rigor
was applied in this study, including a data safety
monitoring board, independent event adjudication by the
clinical events committee, and core laboratory analyses of
all echocardiography indices. The rigor of our audited
follow-up makes our dataset robust.
Because this was a multicenter study, surgeon variability
was a factor in how the procedure was performed. As noted,
awidevariety of different annuloplasty deviceswas used and
performancewas not distinguishable, perhaps because of the
small number of each device type used or perhaps there is
no difference among the repair devices! In the last few years,
greater precision of leaflet coaptation measurement has been
obtained with 3-dimensional echocardiography.14 With this
improved granularity in our echocardiographic studies of
FMR, we will be better able to predict which patients are
at risk for recurrent MR.
A question prompted by this study was ‘‘How and when
do we grade MR?’’ Although the echocardiography labora-
tory has precise criteria for measurements, there are other
methodological issues. FMR is variable by nature according
to patient loading conditions. Varying baseline conditions
were accommodated by accepting the baseline transtho-
racic echocardiogram within 1 month of the surgery. Sev-
eral other phenomena were also observed. Eccentric jets
that were not appreciated on preoperative transthoracic
echocardiography were occasionally noted on theardiovascular Surgery c Volume 141, Number 1 93
TABLE 3. Echocardiography core laboratory analysis in 73 patients treated by coronary artery bypass grafting and mitral repair
Baseline 1 y 1.5 y 2 y
MR grade 2.54  0.81 (N ¼ 70) 0.52  0.66* (N ¼ 46) 0.35  0.63* (N ¼ 33) 0.48  0.62* (N ¼ 26)
LVEF 37.9  11.7 (N ¼ 67) 47.0  12.5y (N ¼ 46) 46.5  11.8y (N ¼ 33) 47.0  12.9z (N ¼ 25)
LVED (cm) 5.83  0.68 (N ¼ 60) 5.34  0.86y (N ¼ 38) 5.55  0.80 (N ¼ 26) 5.16  0.75z (N ¼ 17)
LVES (cm) 4.66  0.89 (N ¼ 57) 3.94  1.08y (N ¼ 35) 4.26  1.03 (N ¼ 23) 3.96  0.95z (N ¼ 17)
MR, Mitral regurgitation; LVEF, left ventricular ejection fraction; LVED, left ventricular end diastolic; LVES, left ventricular end systolic. Mixed model, pairwise comparison
versus baseline, adjusted for multiple comparisons. *P<.001. yP ¼ .001. zP ¼ .01.
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Additionally, as previously reported,3 the degree of intrao-
perative MR was often downgraded compared with the
baseline study. Accurate numeric quantification was diffi-
cult because many of the current methods of assessing
MR, such as proximal isovelocity surface area, are based
on assumptions applicable to structural disease, but not to
the broad jet origins and multiple jets present in functional
disease.
It is important to note that this study documented a recur-
rence of moderate MR in 16% of the patients with a mean
follow-up of 2 years. This is significantly lower than the per-
centagesuggestedbyothers.12Wecould speculate that this dif-
ference is related to the rigor applied to selecting patients with
pure functional MR and ‘‘reasonable’’ ventricular sizes, and
the avoidance of recent transmural myocardial infarctions.15
This study demonstrates the difficulty in recruiting pa-
tients for such a surgical study. The surgeon (not being
a gatekeeper) was typically called in to see a catheterization
film (and patient) the day before a requested surgery. There
was rarely an echocardiogram done before the catheteriza-
tion. This presented a logistic nightmare to screen the pa-
tient, obtain an echocardiogram for the core laboratory to
review, and arrange for trial personnel to be available.
Such issues are being encountered in patient recruitment
with the current National Institutes of Health Cardiac Re-
search Network trials.Limitations
Core laboratory analysis failed to retrospectively confirm
at least moderate MR on a few baseline transthoracic echo-
cardiograms because of incomplete views. These patients
had confirmed moderate MR on intraoperative transesopha-
geal echocardiography. The study was designed in 2002 and
2003 and did not capture all the data of interest that we
would want to capture today, such as serial B-type natri-TABLE 4. Occurrences of primary adverse events during follow-up
PAE event N ¼ 73
Death 18 (24.7%)
Stroke 5 (6.8%)
Myocardial infarction 5 (6.8%)
All cardiac reoperation 4 (5.5%)
Reoperation for repair dysfunction 1 (1.6%)
PAE, Pulmonary air embolism.
94 The Journal of Thoracic and Cardiovascular Surgeuretic peptide levels and baseline cardiac magnetic reso-
nance imaging scans. As noted in the Discussion section,
the individual surgeon chose the annuloplasty device and
sizing strategy for RA; mandating such was beyond the
scope of this trial. In addition, the low number of significant
MR recurrences limits the statistical capability to identify
any suboptimal repair techniques.CONCLUSIONS
CABG þ RA for FIMR predictably reduces MR and
relieves symptoms. This operative strategy for the treatment
of moderate to severe MR is associated with improved indi-
ces of ventricular geometry, improved New York Heart As-
sociation functional class, and excellent freedom from
recurrent mitral insufficiency. Although long-term progno-
sis remains guarded, this multicenter study delineates the
intermediate benefits of such an approach. This study sets
a benchmark for the design and execution of a study pertain-
ing to surgically treated FMR.References
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DDiscussion
Dr Vince Gaudiani (Redwood City, Calif). This article shows
that some of our best surgical groups can achieve excellent pallia-
tion in medium-risk patients with ischemicMR using coronary by-
pass and annuloplasty ring.
Ischemic MR occurs because the mitral annulus is dilated and
the posterior LV wall and chordal apparatus do not function
correctly. A ring can reduce the size of the annulus but it cannot
untether the chordal apparatus. As a profession, we spend a sub-
stantial amount of effort devising rings to reduce annular size but
less time trying to understand how the posterior wall contributes
to mitral valve function. There are 3 factors that alone or in any
combination can delay or reduce the forward motion of the mitral
subvalve apparatus: posterior wall ischemia that could conceiv-
ably be improved by bypassing, posterior wall fibrosis as the re-
sult of infarction, or delayed electrical activation from right
ventricular apex pacing or left bundle branch block. If the poste-
rior wall is ischemic, CABG and ring annuloplasty will be effec-The Journal of Thoracic and Ctive, and I imagine that most of these 75 patients whose condition
improved had just that problem. If there is posterior wall fibrosis
from infarction or frank aneurysmal change, the situation will be
different. Finally, there is abundant evidence that right ventricular
apex pacing and left bundle branch block double the risk of heart
failure requiring hospitalization at every level of LV function.
Therefore, we must begin to look at electrocardiograms as care-
fully as we look at echocardiograms. Biventricular pacing is an
important adjunct to CABG and annuloplasty in these patients
with increased LV size and prolonged QR restoration. It is also
important to point out that LV inferior wall removal and restruc-
turing plus or minus mitral valve replacement is effective in pa-
tients who have large dead inferior walls, but because we
discuss this topic as if ischemic MR were one entity rather than
the group of entities I just described, I think we frequently miss
the point.
Did the 2 patients who required mitral valve replacement
have dead inferior walls, and how many of these patients had
left bundle branch block or were paced from the right ventricu-
lar apex?
Dr Grossi. I can give you a bit of information about activation
times, and this is an observation. We have not dug this out, but pa-
tients who were treated with ventricular reshaping postoperatively
had narrower QRS complexes. We do not know what that truly
means. It was associated with differences in survival, but we really
don’t know whether it was due to a difference in activation times.
What I can tell you is that approximately two thirds of these pa-
tients had inferior wall function, either akinesia or paradoxing mo-
tion (subnormal motion). Of these patients, approximately 25%
improved in terms of their inferior wall function as seen on
segmental echocardiogram analysis. Approximately 15% had
worsening of their inferior walls.ardiovascular Surgery c Volume 141, Number 1 95
APPENDIX 1. Randomized Evaluation of a Surgical Treatment for
Off-Pump Repair of the Mitral Valve investigational sites
Site PI
Aspirus Wausau Hospital (Wis) Fernando Riveron
Baystate Medical Center (Mass) John Rousou
Covenant Healthcare Medical
Center (Mich)
Norbert Baumgartner
Duke University (NC) R. Duane Davis
Emory University (Ga) Thomas Vassiliades
Enloe Medical Center (Calif) Li Poa
Escorts Heart Institute and
Research Centre (India)
Yugal Mishra
Geisinger Health System (Pa) Alfred Casale
Hospital of the University of
Pennsylvania (Pa)
Y. Joseph Woo
Indraprastha Apollo Naresh Trehan/Sanjay Mittal
Lankenau Hospital (Pa) Francis Sutter/Scott Goldman
Lenox Hill Hospital (NY) Valvanur Subramanian/Nirav Patel
Nebraska Heart Institute Lincoln
(Neb)
James Wudel
Nebraska Heart Institute Omaha
(Neb)
Deepak Gangahar
New York University Hospital -
Tisch (NY)
Eugene Grossi
New York University Medical
Center - VA (NY)
Eugene Grossi
Northwest Surgical Associates/
Legacy (Ore)
Thomas Malloy
Prairie Education and Research
Cooperative (Ill)
Carl Arentzen
Rhode Island Hospital (RI) Arun Singh
Spectrum Health (Mich) Charles Willekes
St Joseph Mercy Hospital (Mich) Benjamin McCallister
St Joseph’s (Md) Kimble Jett/John Laschinger
St Josephs Hospital and Medical
Center (Ariz)
Michael Caskey
St Joseph’s Hospital of Atlanta (Ga) J. Allan Wolfe
St Luke’s Hospital (Pa) Terrence Theman
St Luke’s (Wis) David Kress
Stony Brook University Hospital
(NY)
Thomas Bilfinger/Todd Rosengart
The Cleveland Clinic Foundation
(Ohio)
Tomislav Mihaljevic
VA Pittsburgh Healthcare System
(Pa)
Marco Zenati
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APPENDIX 2. Study inclusion/exclusion criteria
These criteria were selected by the sponsor in collaboration
with the FDA. The philosophy of the study design was to (1)
select patients with pure functional MR in whom there was
enough disease to warrant valvular intervention and (2)
select patients whose comorbidities would be associated
with sufficient survival to allow assessment of device
therapy.
Inclusion criteria (patients were included if they met all
of the following criteria):
1. Grade 2, 3, or 4 functional mitral valve regurgitation
per 2-dimensional echocardiography. For the purpose
of this study, functional mitral valve regurgitation is
defined as mitral valve dysfunction caused by dilation
of the mitral valve annulus, displacement of the LV
papillary muscles, chordal tethering of the mitral
valve leaflets, or any combination of these character-
istics. This was core laboratory verified.
2. Patient undergoing concomitant coronary artery by-
pass graft surgery, either on-pump or off-pump
(CABG or OP-CAB).
3. LV ejection fraction>25% per 2-dimensional echo-
cardiography.
4. Age between 18 and 80 years, inclusive.
5. Patient willing and available to return for study
follow-up.
6. Ability of the patient or legal representative to under-
stand and provide signed consent for participating in
the study.
Exclusion criteria (patients were excluded from study
participation if they met any of the following criteria):
1. Structural abnormality of the mitral valve (eg, calci-
fication or thickening of valve leaflets, ruptured pap-
illary muscle, ruptured chordae tendinea, mitral
valve prolapse, mitral stenosis)
2. Organic valve disease resulting in insufficiency or
stenosis of the aortic, pulmonary or tricuspid valve
requiring surgical intervention
3. Transmural myocardial infarction within 30-day pe-
riod before surgical placement of Coapsys (Myocor
Inc, Maple Grove, Minn)
4. NYHA class IV
5. LVED diameter>7.0 cm
6. Cardiac surgery on an emergency or salvage basis
7. Left atrial or LV thrombus
8. LV aneurysm
9. Previous mitral valve surgery or other previous car-
diac surgery that would preclude proper placement
of the Coapsys
10. Chronic renal failure requiring dialysis
11. Open chest surgery contraindication (eg, acute
respiratory distress, endocarditis, myocarditis, peri-
carditis)
12. Active infection
13. Life expectancy of<12 mo
14. Participation in another investigational drug or de-
vice protocol
FDA, Food and Drug Administration;MR,mitral regurgi-
tation; OP-CAB, off-pump coronary artery bypass; CABG,
coronary artery bypass grafting; LV, left ventricular;
NYHA,NewYork Heart Association; LVED, left ventricular
end diastolic.
APPENDIX 3. Details of patients with recurrent mitral insufficiency
(n ¼ 12)
Mean ejection fraction 37.4%
Mean LVEDD (cm) 6.1 cm
Soft annuloplasty device used 1 (8.3%)
Annuloplasty device>28 mm 7 (58.3%)
LVEDD, Left ventricular end-diastolic diameter.
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